ArticleCureus2026
Unexpected Pericardial Cytology in a Patient With Primary Squamous Cell Carcinoma of the Lung: Emphasizing the Need for Advanced Molecular Characterization of Tumors.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) encompasses a diverse group of histologic subtypes, including adenocarcinoma, squamous cell carcinoma (SqCC), and the less common but clinically aggressive adenosquamous carcinoma. Intratumoral histologic heterogeneity is a recognized challenge in NSCLC and may result in diagnostic discordance when sampling is limited. Cytologic-pathologic discordance may raise concern for tumor heterogeneity, sampling error, or misidentified histologic subtype. In such scenarios, molecular profiling and re-biopsy are essential to refine diagnosis and guide therapy. Here, we present a case of a 70-year-old man with a known history of SqCC of the lung who presented with progressive shortness of breath and was found to have a large pericardial effusion. Cytologic analysis of the pericardial fluid revealed malignant adenocarcinoma cells, discordant with the prior SqCC diagnosis. Molecular profiling of the pericardial fluid identified a TP53 mutation, intermediate tumor mutational burden, and microsatellite stability, without actionable oncogenic drivers. Repeat tissue sampling reconfirmed SqCC histology with high PD-L1 expression. The patient was initially treated with pembrolizumab monotherapy but required escalation to carboplatin, pemetrexed, and pembrolizumab due to disease progression. The cytologic discordance raised suspicion for unrecognized adenosquamous carcinoma or tumor heterogeneity not captured on initial biopsy. No evidence of a second primary malignancy or histologic transformation was found. This case highlights the diagnostic challenges and therapeutic implications of cytologic-pathologic discordance in NSCLC. It underscores the importance of molecular profiling and repeat tissue sampling in guiding personalized treatment decisions when histologic uncertainty exists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.